Evicenter
MarkdownMedical informationP&T meetings
Deucrictibant (PHA121)

On-demand treatment of hereditary angioedema attacks

Also known as PHA-022121
Manufacturer
Pharvaris
Last updated
209 sources

Clinical evidence

PHA121-C001

34 evidence topics · 7 sources

Objective
Location and study date
Study design
Cohorts: pharmacokinetic part 1 and pharmacodynamic part 2
CohortParticipants
Part 1 (PK), 1 mg, fasted“N=6”
Part 1 (PK), 2 mg, fasted“N=6”
Part 1 (PK), 4.5 mg, fasted“N=6”
Part 1 (PK), 12 mg, fasted“N=6”
Part 1 (PK), 22 mg, fasted“N=6”
Part 1 (PK), 22 mg, after high-calorie, high-fat breakfast“N=6”
Part 1 (PK), placebo“N=12”
Part 2 (PD), 12 mg, fasted“N=8”
Part 2 (PD), 22 mg, fasted“N=8”
Part 2 (PD), placebo“N=4”
Eligibility criteria
Treatment
Study outcomes
Rationale for using safety and tolerability as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics

No evidence found.

Efficacy results
Pharmacokinetic parameters by dose (N=6 per dose)
Bradykinin challenge: modeled duration of effect compared with icatibant 30 mg
ResponseIcatibant 30 mg (s.c.)PHA121 12 mg (oral)PHA121 22 mg (oral)
Diastolic blood pressure, time (h) above EC50 at a 75% confidence level“6”“11.5”“14”
Mean arterial blood pressure, time (h) above EC50 at a 75% confidence level“6”“12”“15.5”
Heart rate, time (h) above EC50 at a 75% confidence level“6.5”“10”“13”
Diastolic blood pressure, time (h) above EC85 at a 50% confidence level“5.5”“7.5”“10”
Mean arterial blood pressure, time (h) above EC85 at a 50% confidence level“5.5”“7”“10”
Heart rate, time (h) above EC85 at a 50% confidence level“5.5”“6.5”“9.5”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Adverse events by dose group
Dose groupParticipantsAny AE, n (%)Any related AEAny severe AEAny serious AE
1 mg, fasted“N=6”“2 (33.3%)”“0”“0”“0”
2 mg, fasted“N=6”“1 (16.7%)”“0”“0”“0”
4.5 mg, fasted“N=6”“1 (16.7%)”“0”“0”“0”
12 mg, fasted“N=14”“5 (35.7%)”“2 (14.3%)”“0”“0”
22 mg, fasted“N=14”“2 (14.3%)”“1 (7.1%)”“0”“0”
22 mg after HCHF breakfast“N=6”“1 (16.7%)”“0”“0”“0”
Placebo“N=16”“5 (31.3%)”“1 (6.3%)”“0”“0”
Study limitations
Summary
  • PHA121-C001 enrolled healthy volunteers, who received single doses up to 22 mg given as an oral solution.
  • Pharmacokinetic cohorts had six participants per dose, and the food effect was assessed in one cohort of six participants at 22 mg. The higher AUCinf after a high-calorie, high-fat breakfast was reported as “mainly caused by one outlier”, and the AUC increase is reported as 49% and as 42% in different documents.
  • The pharmacodynamic evidence comes from a bradykinin challenge in 16 healthy volunteers receiving 12 or 22 mg, a surrogate used for icatibant dose selection, and the results were compared with published icatibant results.
  • Safety was followed for 72 hours after a single dose.
  • The results are reported in two posters described in a company press release and in the company's registration statement.